Oncode Investigators

Oncode is conceived around the concept of bringing truly outstanding fundamental oncology researchers together. At the outset Oncode invited 43 top scientists in fundamental oncology from across the Netherlands to join Oncode’s initial scientific team. The initial 43 Oncode Investigators bring in their own research groups, totaling 560 scientists. The scientists affiliated with Oncode commit themselves to a common, integrated research program.

These scientists are employed at Oncode's partner institutions: AMC, Erasmus MC, Hubrecht Institute, LUMC, NKI, Radboudumc, Radboud University, Princess Máxima Center and UMC Utrecht. 

  • Reuven Agami NKI
  • René Bernards NKI
  • Anton Berns NKI
  • Hans Bos UMC Utrecht
  • Thijn Brummelkamp NKI
  • Boudewijn Burgering UMC Utrecht
  • Hans Clevers Princess Máxima Center
    & Hubrecht Institute
  • Edwin Cuppen UMC Utrecht
  • Wouter de Laat Hubrecht Institute
  • Karin de Visser NKI
  • Elzo de Wit NKI
  • Ruud Delwel Erasmus MC
  • Monique den Boer Princess Máxima Center
    & Erasmus MC
  • Carl Figdor Radboudumc
  • Joost Gribnau Erasmus MC
  • Jan Hoeijmakers Princess Máxima Center
    & Erasmus MC
  • Jos Jonkers NKI
  • Roland Kanaar Erasmus MC
  • Jop Kind Hubrecht Institute
  • Puck Knipscheer Hubrecht Institute
  • Geert Kops Hubrecht Institute
  • Susanne Lens UMC Utrecht
  • Jurgen Marteijn Erasmus MC
  • Madelon Maurice UMC Utrecht
  • Jan Paul Medema AMC
  • René Medema NKI
  • Linde Meyaard UMC Utrecht
  • Sjaak Neefjes LUMC
  • Huib Ovaa LUMC
  • Daniël Peeper NKI
  • Ton Schumacher NKI
  • Titia Sixma NKI
  • Hugo Snippert UMC Utrecht
  • Marvin Tanenbaum Hubrecht Institute
  • Peter ten Dijke LUMC
  • Maarten van Lohuizen NKI
  • Alexander van Oudenaarden Hubrecht Institute
  • Jacco van Rheenen NKI
  • Bas van Steensel NKI
  • Wim Vermeulen Erasmus MC
  • Michiel Vermeulen Radboud University
  • Lodewyk Wessels NKI
  • Wilbert Zwart NKI

Supervisory Board

The Supervisory Board has the duty to supervise the policy of the Managing Board and the general conduct of business of Oncode.

The Supervisory Board will be complete when it counts seven members, including an independent chair. The UMCs, the research institutes, the Government and KWF Kankerbestrijding are each entitled to nominate a member. The other two members originate from the community of patients and industry.

Oncode is in the process of selecting members for the Supervisory Board.

Eduard Klasen

Chair

Edvard Beem

Member

René Kuijten

Member

Managing Board

The members of the Managing Board operate and manage Oncode, taking into account that Oncode has an important social responsibility. The Managing Board consists of a General Director, Valorization Director and a Chief Scientific Officer.

Research Management Committee

The Research Management Committee provides guidance and policy advice to the Managing Board on research related themes.

Partner
Institutions

The scientists collaborating within Oncode are, or will be, employed at one or more of Oncode’s partner institutions, at present: five UMCs, three research institutes and one university. With no research facilities of its own, Oncode operates as a virtual institute with a small staff consisting of a general support team and a team of valorization experts. In the near future, it is expected that other institutions will join Oncode.

Funders

Oncode could not exist without financial support from our dedicated funders KWF Kankerbestrijding, the Dutch Government (the Ministry of Economic Affairs, Ministry of Education, Culture and Science, Ministry of Health, Welfare and Sport and the Top Sector Life Sciences & Health) and our partner institutions.

About the name

For Oncode Institute it all starts with oncology, the prevention, diagnosis, and treatment of cancer. Through fundamental research, our institute strives for a deeper understanding of the basics of cancer: the ‘code’.

Oncode Institute aims to decode cancer: to understand and identify the harmful irregularities in every person’s unique genome. Our logo represents the genome code, including these harmful errors. To represent that cancer is ever-changing a programming script was written that generates a dynamic code. This creates a logo that captures the unique variations of cancer.

Our Goal

Helping more patients survive, improving the quality of life for those afflicted, and ultimately curing cancer.

The complexity of cancer calls for strategic action and collaboration. Oncode is a new initiative that joins established forces in the Dutch research world to do precisely that. Instead of new buildings, we are constructing a network, in which experienced, leading scientists and gifted young researchers at partner institutions strive together toward a greater, common goal, supported by KWF Kankerbestrijding and the Dutch Government.

Because only by working together we can outsmart cancer.

Thank you for your interest in Oncode. If you have any questions or suggestions, please feel free to contact us at anytime.

info@oncode.nl

Alexa Tjeenk Willink

Chief Operations Officer



Oncode on the ANBI website.